TY  - BOOK
AU  - Ratner, Robert E
TI  - Pioglitazone slows progression of atherosclerosis  in prediabetes independent of changes in cardiovascular risk  factors
SN  - 1079-5642
PY  - 2013///
KW  - *Carotid Artery Diseases/pc [Prevention & Control]
KW  - *Diabetes Mellitus, Type 2/pc [Prevention &  Control]
KW  - *Hypoglycemic Agents/tu [Therapeutic Use]
KW  - *Prediabetic State/dt [Drug Therapy]
KW  - *Thiazolidinediones/tu [Therapeutic Use]
KW  - Adiponectin/bl [Blood]
KW  - Adult
KW  - Aged
KW  - Biological Markers/bl [Blood]
KW  - Blood Glucose/de [Drug Effects]
KW  - Blood Glucose/me [Metabolism]
KW  - Carotid Artery Diseases/bl [Blood]
KW  - Carotid Artery Diseases/di [Diagnosis]
KW  - Carotid Artery Diseases/et [Etiology]
KW  - Carotid Intima-Media Thickness
KW  - Chi-Square Distribution
KW  - Cholesterol, HDL/bl [Blood]
KW  - Diabetes Mellitus, Type 2/bl [Blood]
KW  - Diabetes Mellitus, Type 2/di [Diagnosis]
KW  - Diabetes Mellitus, Type 2/et [Etiology]
KW  - Disease Progression
KW  - Double-Blind Method
KW  - Female
KW  - Hemoglobin A, Glycosylated/me [Metabolism]
KW  - Humans
KW  - Insulin/bl [Blood]
KW  - Linear Models
KW  - Male
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Plasminogen Activator Inhibitor 1/bl [Blood]
KW  - Prediabetic State/bl [Blood]
KW  - Prediabetic State/co [Complications]
KW  - Prediabetic State/di [Diagnosis]
KW  - Prospective Studies
KW  - Risk Assessment
KW  - Risk Factors
KW  - Time Factors
KW  - Treatment Outcome
KW  - United States
KW  - MedStar Health Research Institute
KW  - Journal Article
KW  - Multicenter Study
KW  - Randomized Controlled Trial
KW  - Research Support, Non-U.S. Gov't
KW  - Research Support, U.S. Gov't, Non-P.H.S
N1  - Available online from MWHC library: 1995 - present
N2  - CONCLUSIONS: Pioglitazone slowed progression of  CIMT, independent of improvement in hyperglycemia, insulin  resistance, dyslipidemia, and systemic inflammation in  prediabetes. These results suggest a possible direct  vascular benefit of pioglitazone; METHODS AND RESULTS: CIMT was measured in 382  participants at the beginning and up to 3 additional times  during follow-up of the Actos Now for Prevention of Diabetes  trial. During an average follow-up of 2.3 years, the mean  unadjusted annual rate of CIMT progression was significantly  (P=0.01) lower with pioglitazone treatment (4.76x10(-3)  mm/year; 95% CI: 2.39x10(-3)-7.14x10(-3) mm/year) compared  with placebo (9.69x10(-3) mm/year; 95% CI:  7.24x10(-3)-12.15x10(-3) mm/year). High-density lipoprotein  cholesterol, fasting and 2-hour glucose, HbA(1c), fasting  insulin, Matsuda insulin sensitivity index, adiponectin, and  plasminogen activator inhibitor-1 levels improved  significantly with pioglitazone treatment compared with  placebo (P<0.001). However, the effect of pioglitazone on  CIMT progression was not attenuated by multiple methods of  adjustment for traditional, metabolic, and inflammatory risk  factors and concomitant medications, and was independent of  changes in risk factors during pioglitazone treatment; OBJECTIVE: To determine whether changes in  standard and novel risk factors during the Actos Now for  Prevention of Diabetes trial explained the slower rate of  carotid intima media thickness (CIMT) progression with  pioglitazone treatment in persons with prediabetes
UR  - http://dx.doi.org/10.1161/ATVBAHA.112.300346
ER  -